JP2014526469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526469A5 JP2014526469A5 JP2014529913A JP2014529913A JP2014526469A5 JP 2014526469 A5 JP2014526469 A5 JP 2014526469A5 JP 2014529913 A JP2014529913 A JP 2014529913A JP 2014529913 A JP2014529913 A JP 2014529913A JP 2014526469 A5 JP2014526469 A5 JP 2014526469A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 230000009529 traumatic brain injury Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 229940127240 opiate Drugs 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 230000000698 schizophrenic effect Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 0 C1C2(CCC*3)C33C2C1*3 Chemical compound C1C2(CCC*3)C33C2C1*3 0.000 description 3
- PYJAYEGNRABCLY-SVAFWTMJSA-N CC(C)(CCC(C)(C)O)[C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(C)(CCC(C)(C)O)[C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 PYJAYEGNRABCLY-SVAFWTMJSA-N 0.000 description 1
- CEBHHEZNBBYQSM-KRGDYOPUSA-N CC(C)C(CC[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O Chemical compound CC(C)C(CC[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O CEBHHEZNBBYQSM-KRGDYOPUSA-N 0.000 description 1
- QLQYZOMZOGPIOC-QTFZZFSVSA-N CC(C)C(CO[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O Chemical compound CC(C)C(CO[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O QLQYZOMZOGPIOC-QTFZZFSVSA-N 0.000 description 1
- CKIKDYISGBHWPU-MHLXRUGDSA-N CC(CC(CO)(F)F)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CC(CO)(F)F)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 CKIKDYISGBHWPU-MHLXRUGDSA-N 0.000 description 1
- CHGDJFGOJYCPHZ-QQHYONEASA-N CC(CCC(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 CHGDJFGOJYCPHZ-QQHYONEASA-N 0.000 description 1
- GUUYVPWCEUMENE-SHOUTUCRSA-N CC(CCC1(CC1)O)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC1(CC1)O)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 GUUYVPWCEUMENE-SHOUTUCRSA-N 0.000 description 1
- PQNBSROBFNWPRX-XLUYLUSISA-N CC(CCCO)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCCO)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 PQNBSROBFNWPRX-XLUYLUSISA-N 0.000 description 1
- HBKQWULJDAALRY-NLIMMPQESA-N CC([C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1)C(CO)(F)F Chemical compound CC([C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1)C(CO)(F)F HBKQWULJDAALRY-NLIMMPQESA-N 0.000 description 1
- RVXHMRSBDNBDEY-UHFFFAOYSA-N CCOC(C(C)C)(F)F Chemical compound CCOC(C(C)C)(F)F RVXHMRSBDNBDEY-UHFFFAOYSA-N 0.000 description 1
- VOXRDLZRMKBAFE-UHFFFAOYSA-N CCO[IH][IH]CC(C)OCC(C)(F)F Chemical compound CCO[IH][IH]CC(C)OCC(C)(F)F VOXRDLZRMKBAFE-UHFFFAOYSA-N 0.000 description 1
- UIIQWGBQZPMASR-UHFFFAOYSA-N COCC(F)(F)I Chemical compound COCC(F)(F)I UIIQWGBQZPMASR-UHFFFAOYSA-N 0.000 description 1
- ZOOUPKHXFIPMMF-DYNRJKDWSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O ZOOUPKHXFIPMMF-DYNRJKDWSA-N 0.000 description 1
- XDYKAHLZXSUEFM-FQJGFYLYSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OCC(C(F)(F)F)=O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OCC(C(F)(F)F)=O XDYKAHLZXSUEFM-FQJGFYLYSA-N 0.000 description 1
- RJXMOBXFLJYGMG-GRMHXZAGSA-N C[C@@](CC1)([C@@H](CCCC(O)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 Chemical compound C[C@@](CC1)([C@@H](CCCC(O)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 RJXMOBXFLJYGMG-GRMHXZAGSA-N 0.000 description 1
- HSPFXQHDOBRBLE-QRIWCCNGSA-N C[C@@](CC1)([C@@H](COCC(C(F)(F)F)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 Chemical compound C[C@@](CC1)([C@@H](COCC(C(F)(F)F)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 HSPFXQHDOBRBLE-QRIWCCNGSA-N 0.000 description 1
- LSWHPMWXDZERPR-IVFIPZGWSA-N C[C@H](CC(C(F)(F)F)=O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2C(C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC(C(F)(F)F)=O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2C(C)(CC[C@@](C)(C2)O)C2=CC1 LSWHPMWXDZERPR-IVFIPZGWSA-N 0.000 description 1
- BJHUPERNCXCFTH-JFBOSTTDSA-N C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CCC(C2)=O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CCC(C2)=O)C2=CC1 BJHUPERNCXCFTH-JFBOSTTDSA-N 0.000 description 1
- LLAUXVXYDZUXBL-VKHMYHEASA-N C[C@H](OC(C)(F)F)I Chemical compound C[C@H](OC(C)(F)F)I LLAUXVXYDZUXBL-VKHMYHEASA-N 0.000 description 1
- ZOOUPKHXFIPMMF-HZKWPTRHSA-N C[C@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O Chemical compound C[C@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O ZOOUPKHXFIPMMF-HZKWPTRHSA-N 0.000 description 1
- ZZLABZROPODDLV-DNCNGORPSA-N C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCC(C(F)(F)F)=O Chemical compound C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCC(C(F)(F)F)=O ZZLABZROPODDLV-DNCNGORPSA-N 0.000 description 1
- JLWWULDDVJQPID-HHZWQIATSA-N C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCCC(C(F)(F)F)=O Chemical compound C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCCC(C(F)(F)F)=O JLWWULDDVJQPID-HHZWQIATSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532427P | 2011-09-08 | 2011-09-08 | |
| US61/532,427 | 2011-09-08 | ||
| PCT/US2012/054261 WO2013036835A1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017169737A Division JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526469A JP2014526469A (ja) | 2014-10-06 |
| JP2014526469A5 true JP2014526469A5 (OSRAM) | 2015-10-29 |
| JP6205362B2 JP6205362B2 (ja) | 2017-09-27 |
Family
ID=46964032
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529913A Active JP6205362B2 (ja) | 2011-09-08 | 2012-09-07 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2017169737A Withdrawn JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2019011169A Active JP6777773B2 (ja) | 2011-09-08 | 2019-01-25 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2020170611A Withdrawn JP2021008504A (ja) | 2011-09-08 | 2020-10-08 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2025064398A Pending JP2025108535A (ja) | 2011-09-08 | 2025-04-09 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017169737A Withdrawn JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2019011169A Active JP6777773B2 (ja) | 2011-09-08 | 2019-01-25 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2020170611A Withdrawn JP2021008504A (ja) | 2011-09-08 | 2020-10-08 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2025064398A Pending JP2025108535A (ja) | 2011-09-08 | 2025-04-09 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20150158903A1 (OSRAM) |
| EP (2) | EP4245369A3 (OSRAM) |
| JP (5) | JP6205362B2 (OSRAM) |
| CN (4) | CN103958540B (OSRAM) |
| AU (6) | AU2012304412A1 (OSRAM) |
| BR (1) | BR112014005373B1 (OSRAM) |
| CA (1) | CA2848212C (OSRAM) |
| DK (1) | DK2753632T3 (OSRAM) |
| ES (1) | ES2951664T3 (OSRAM) |
| FI (1) | FI2753632T3 (OSRAM) |
| HR (1) | HRP20230747T1 (OSRAM) |
| HU (1) | HUE062616T2 (OSRAM) |
| LT (1) | LT2753632T (OSRAM) |
| PL (1) | PL2753632T3 (OSRAM) |
| PT (1) | PT2753632T (OSRAM) |
| RS (1) | RS64332B1 (OSRAM) |
| RU (1) | RU2665571C2 (OSRAM) |
| SI (1) | SI2753632T1 (OSRAM) |
| SM (1) | SMT202300232T1 (OSRAM) |
| WO (1) | WO2013036835A1 (OSRAM) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| EP1959966B1 (en) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| RS67266B1 (sr) * | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| RU2021111681A (ru) * | 2013-03-13 | 2021-05-11 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2014169832A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169836A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| HRP20210610T1 (hr) | 2013-07-19 | 2021-05-28 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihove uporabe |
| PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| SMT202200094T1 (it) | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US20170304321A1 (en) * | 2014-10-07 | 2017-10-26 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| EP4275748A3 (en) | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3885352B1 (en) | 2014-10-16 | 2024-11-27 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| RS60343B1 (sr) | 2014-11-27 | 2020-07-31 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| SMT202100476T1 (it) * | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| BR112018000129B1 (pt) * | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| EP3328817A4 (en) * | 2015-07-30 | 2019-04-03 | Intercept Pharmaceuticals, Inc. | PROCESS FOR THE PRODUCTION OF GALLENIC ACIDS AND DERIVATIVES THEREOF |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2017149052A1 (en) * | 2016-03-02 | 2017-09-08 | Patheon Austria Gmbh Co. & Kg | Process and intermediates for the production of 17(20)-ene b-seco steroids |
| CN113616661A (zh) | 2016-03-08 | 2021-11-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| SI3436022T1 (sl) * | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) * | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) * | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| WO2018026781A1 (en) | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| CN110267966B (zh) * | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP4105223B1 (en) * | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
| AU2018234692B2 (en) | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CN109280069B (zh) * | 2017-07-19 | 2020-09-04 | 青岛海洋生物医药研究院股份有限公司 | 3β-羟基-麦角甾-5-烯甾类衍生物及其药物用途 |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| IT201700100483A1 (it) * | 2017-09-07 | 2019-03-07 | Dipharma Francis Srl | Ossidazione selettiva dell’acido iodesossicolico |
| US20220023315A1 (en) * | 2018-07-31 | 2022-01-27 | The Research Foundation For The State University Of New York | Methods of activating microglial cells |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061332A1 (en) * | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Sterol analogs and uses thereof |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| KR102821994B1 (ko) | 2019-01-08 | 2025-06-19 | 쳉두 캉홍 파마슈티칼 코., 엘티디. | 스테로이드 화합물, 및 이의 용도와 제조방법 |
| AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
| US20230303616A9 (en) * | 2019-06-27 | 2023-09-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| IL293525A (en) | 2019-12-06 | 2022-08-01 | Marinus Pharmaceuticals Inc | Ganaxolone for use in the treatment of multiple sclerosis complex |
| CN113387991B (zh) * | 2020-03-13 | 2024-06-18 | 苏州朗科生物技术股份有限公司 | 一种合成地屈孕酮的方法及化合物 |
| JP2023518411A (ja) * | 2020-03-18 | 2023-05-01 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその使用方法 |
| CZ309819B6 (cs) * | 2020-10-23 | 2023-11-08 | Univerzita Palackého v Olomouci | Sterolové deriváty, přípravky obsahující tyto deriváty a jejich použití |
| CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
| KR20240035444A (ko) | 2021-06-11 | 2024-03-15 | 세이지 테라퓨틱스, 인크. | 알츠하이머병 치료를 위한 신경활성 스테로이드 |
| US20240417423A1 (en) | 2021-09-22 | 2024-12-19 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| KR102749670B1 (ko) * | 2021-09-28 | 2025-01-03 | 경희대학교 산학협력단 | 신규한 콜린산 유도체 및 이의 용도 |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
| WO2023205801A2 (en) | 2022-04-22 | 2023-10-26 | Asteroid Therapeutics | Steroidal compositions and methods of treating lipogenic cancers |
| AU2023385734A1 (en) * | 2022-11-21 | 2025-06-26 | Sage Therapeutics, Inc. | Negative nmda-modulating compounds and methods of use thereof |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) * | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) * | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| GB1120870A (en) | 1966-07-11 | 1968-07-24 | Ici Ltd | Quinoline derivatives |
| JPS5324071B2 (OSRAM) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| WO1989002272A1 (en) | 1987-08-25 | 1989-03-23 | Gee Kelvin W | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| GEP20002033B (en) * | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| CA2223996A1 (en) * | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| JPH11507929A (ja) | 1995-06-23 | 1999-07-13 | ノボ ノルディスク アクティーゼルスカブ | 減数分裂調節化合物 |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| JP2002514621A (ja) | 1998-05-11 | 2002-05-21 | ノボ ノルディスク アクティーゼルスカブ | 置換グアニジン及びジアミノニトロエテン、それらの製造及び使用 |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| HUP0201818A3 (en) | 1999-04-29 | 2004-04-28 | Euro Celtique Sa | 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| WO2002090375A2 (en) | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| US20030162758A1 (en) | 2001-12-07 | 2003-08-28 | Schwartz Daniel M. | Treatment for age-related macular degeneration (AMD) |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| DE602005025391D1 (de) | 2004-11-01 | 2011-01-27 | Seo Hong Yoo | Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| EP2486924B1 (en) * | 2006-04-22 | 2018-12-26 | Neurmedix, Inc. | Drugs and uses |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| ES2662500T3 (es) | 2006-11-21 | 2018-04-06 | Asarina Pharma Ab | El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central |
| AU2008331808B2 (en) | 2007-03-16 | 2014-08-21 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| US8273737B2 (en) | 2008-01-25 | 2012-09-25 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| CA2722776A1 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| WO2012166617A2 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| SG10201706063UA (en) | 2012-12-18 | 2017-09-28 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物 |
| AU2014212487C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| RU2021111681A (ru) | 2013-03-13 | 2021-05-11 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| EP3900738A1 (en) | 2014-02-08 | 2021-10-27 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| US20170304321A1 (en) | 2014-10-07 | 2017-10-26 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| SMT202100476T1 (it) | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN110267966B (zh) | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
-
2012
- 2012-09-07 WO PCT/US2012/054261 patent/WO2013036835A1/en not_active Ceased
- 2012-09-07 LT LTEPPCT/US2012/054261T patent/LT2753632T/lt unknown
- 2012-09-07 FI FIEP12766766.5T patent/FI2753632T3/fi active
- 2012-09-07 HU HUE12766766A patent/HUE062616T2/hu unknown
- 2012-09-07 PL PL12766766.5T patent/PL2753632T3/pl unknown
- 2012-09-07 US US14/343,603 patent/US20150158903A1/en not_active Abandoned
- 2012-09-07 SM SM20230232T patent/SMT202300232T1/it unknown
- 2012-09-07 CA CA2848212A patent/CA2848212C/en active Active
- 2012-09-07 RU RU2014113548A patent/RU2665571C2/ru active
- 2012-09-07 PT PT127667665T patent/PT2753632T/pt unknown
- 2012-09-07 EP EP23171488.2A patent/EP4245369A3/en active Pending
- 2012-09-07 SI SI201232034T patent/SI2753632T1/sl unknown
- 2012-09-07 CN CN201280054927.2A patent/CN103958540B/zh active Active
- 2012-09-07 ES ES12766766T patent/ES2951664T3/es active Active
- 2012-09-07 CN CN202410996084.2A patent/CN119192267A/zh active Pending
- 2012-09-07 EP EP12766766.5A patent/EP2753632B1/en active Active
- 2012-09-07 JP JP2014529913A patent/JP6205362B2/ja active Active
- 2012-09-07 RS RS20230525A patent/RS64332B1/sr unknown
- 2012-09-07 BR BR112014005373-1A patent/BR112014005373B1/pt active IP Right Grant
- 2012-09-07 DK DK12766766.5T patent/DK2753632T3/da active
- 2012-09-07 AU AU2012304412A patent/AU2012304412A1/en not_active Abandoned
- 2012-09-07 CN CN202111105989.9A patent/CN113956315B/zh active Active
- 2012-09-07 CN CN201711063812.0A patent/CN107936076B/zh active Active
- 2012-09-07 HR HRP20230747TT patent/HRP20230747T1/hr unknown
-
2017
- 2017-06-29 AU AU2017204452A patent/AU2017204452B2/en active Active
- 2017-09-04 JP JP2017169737A patent/JP2018021059A/ja not_active Withdrawn
-
2018
- 2018-08-28 US US16/114,791 patent/US10759828B2/en active Active
-
2019
- 2019-01-25 JP JP2019011169A patent/JP6777773B2/ja active Active
- 2019-09-10 AU AU2019227507A patent/AU2019227507B2/en active Active
-
2020
- 2020-07-29 US US16/942,235 patent/US20210147470A1/en not_active Abandoned
- 2020-10-08 JP JP2020170611A patent/JP2021008504A/ja not_active Withdrawn
-
2021
- 2021-06-21 AU AU2021204183A patent/AU2021204183B2/en active Active
-
2022
- 2022-03-29 US US17/707,303 patent/US12129275B2/en active Active
-
2023
- 2023-05-15 AU AU2023203028A patent/AU2023203028B2/en active Active
-
2024
- 2024-09-23 US US18/893,387 patent/US20250257092A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064398A patent/JP2025108535A/ja active Pending
- 2025-05-26 AU AU2025203873A patent/AU2025203873A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526469A5 (OSRAM) | ||
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| JP2014528485A5 (OSRAM) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2017531020A5 (OSRAM) | ||
| JP2013512926A5 (OSRAM) | ||
| JP2016513663A5 (OSRAM) | ||
| JP2015512951A5 (OSRAM) | ||
| RU2018130727A (ru) | Органические соединения | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP2012530779A5 (OSRAM) | ||
| JP2008524262A5 (OSRAM) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| RU2017119222A (ru) | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения | |
| AR082699A1 (es) | Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto | |
| JP2011132222A5 (OSRAM) | ||
| JP2017533968A5 (OSRAM) | ||
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| JP2012521994A5 (OSRAM) | ||
| JP2017524025A5 (OSRAM) | ||
| JP2017518323A5 (OSRAM) | ||
| JP2011530521A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| JP2018519329A5 (OSRAM) |